Biogen company profile

BIIB · NASDAQ · USD

Compare Biogen
$253.40Change from previous close: +1.17%Absolute change: +$2.92

Close · November 13, 2026

Company profile

Biogen has 7,500 employees and is headquartered in Cambridge, United States.

Biogen's sales reach across the United States, Europe, Germany, Asia and other international markets, where it discovers, develops, manufactures and delivers therapies. Its portfolio centres on treatments for multiple sclerosis, including TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and OCREVUS, alongside SPINRAZA for spinal muscular atrophy, SKYCLARYS for Friedreich's Ataxia, QALSODY for amyotrophic lateral sclerosis and LEQEMBI for Alzheimer's disease. The company also sells biosimilars of ENBREL, HUMIRA and REMICADE, anti-CD20 lymphoma and leukemia therapies such as RITUXAN and GAZYVA, and ZURZUVAE for postpartum depression. It works with partners including Eisai, Genentech, UCB and Samsung Bioepis.

In the fiscal year ended December 2025, Biogen reported revenue of USD 9.9 billion, up 2.2% from the previous year, and net income of USD 1.3 billion. The company employs 7,500 people and is headquartered in Cambridge, Massachusetts, where it was founded in 1978.

Company facts

Industry
Drug Manufacturers - General
Headquarters
225 Binney Street, 02142, Cambridge
Employees
7,500
Chief executive
Christopher Viehbacher
Founded
1978
Fiscal year
January - December
Listing
BIIB · NASDAQ
Indices
S&P 500
Currency
USD
ISIN
US09062X1037
Website
biogen.com

Biogen and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
BiogenBIIBUnited States$37.46B7,50023.5%108.3
Bristol-Myers SquibbBMYUnited States$129.66B32,50032.4%14.1
PfizerPFEUnited States$164.67B75,00029.1%41.3
Gilead SciencesGILDUnited States$208.48B17,00038.2%—
AmgenAMGNUnited States$251.89B31,50034.1%27.0
Merck & Co.MRKUnited States$364.26B73,00035.2%147.8

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Biogen with its competitors